异动解读 | 半年报业绩亮眼，先声药业盘中大涨5.04%

异动解读

Aug 25

8月25日周一盘中，先声药业（02096）股价大涨5.04%，引起市场关注。在港股整体市场表现平淡的背景下，先声药业的强劲表现格外引人注目。

消息面上，先声药业发布了2025年上半年财报，显示公司业绩表现优异。报告期内，公司实现收入35.85亿元人民币，同比增长15.1%；其中创新药业务收入27.76亿元，占比77.4%，同比增长26.0%。归属股东净利润达6.04亿元，增长32.2%。公司三大核心业务领域均有亮眼表现：神经科学领域收入12.49亿元，增长37.3%；抗肿瘤领域收入8.74亿元，增长41.1%；自身免疫领域收入8.78亿元，增长3.3%。研发投入达10.28亿元，占收入的28.7%，彰显公司对创新的持续投入。

分析人士指出，先声药业未来发展潜力巨大。公司创新药管线超过60项，新增科唯可与恩泽舒两款创新药获批，多个研发项目取得重要进展。国际合作方面，公司与艾伯维达成SIM0500三特异性抗体许可选择权协议，展现了自主创新平台的实力。未来催化剂包括创新药管线临床推进、先必新舌下片海外拓展、SIM0500早期数据读出及更多商业开发合作。有分析师给予先声药业16港元的目标价，认为公司业绩增长与估值重塑潜力值得期待。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1132179786"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132179786\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132179786?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-25 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132179786","market":"sg","top_or_hot":-1,"title":"异动解读 | 半年报业绩亮眼，先声药业盘中大涨5.04%","media":"异动解读","content":"<p>8月25日周一盘中，先声药业（02096）股价大涨5.04%，引起市场关注。在港股整体市场表现平淡的背景下，先声药业的强劲表现格外引人注目。</p>\n\n<p>消息面上，先声药业发布了2025年上半年财报，显示公司业绩表现优异。报告期内，公司实现收入35.85亿元人民币，同比增长15.1%；其中创新药业务收入27.76亿元，占比77.4%，同比增长26.0%。归属股东净利润达6.04亿元，增长32.2%。公司三大核心业务领域均有亮眼表现：神经科学领域收入12.49亿元，增长37.3%；抗肿瘤领域收入8.74亿元，增长41.1%；自身免疫领域收入8.78亿元，增长3.3%。研发投入达10.28亿元，占收入的28.7%，彰显公司对创新的持续投入。</p>\n\n<p>分析人士指出，先声药业未来发展潜力巨大。公司创新药管线超过60项，新增科唯可与恩泽舒两款创新药获批，多个研发项目取得重要进展。国际合作方面，公司与艾伯维达成SIM0500三特异性抗体许可选择权协议，展现了自主创新平台的实力。未来催化剂包括创新药管线临床推进、先必新舌下片海外拓展、SIM0500早期数据读出及更多商业开发合作。有分析师给予先声药业16港元的目标价，认为公司业绩增长与估值重塑潜力值得期待。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 半年报业绩亮眼，先声药业盘中大涨5.04%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 半年报业绩亮眼，先声药业盘中大涨5.04%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-08-25 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>8月25日周一盘中，先声药业（02096）股价大涨5.04%，引起市场关注。在港股整体市场表现平淡的背景下，先声药业的强劲表现格外引人注目。</p>\n\n<p>消息面上，先声药业发布了2025年上半年财报，显示公司业绩表现优异。报告期内，公司实现收入35.85亿元人民币，同比增长15.1%；其中创新药业务收入27.76亿元，占比77.4%，同比增长26.0%。归属股东净利润达6.04亿元，增长32.2%。公司三大核心业务领域均有亮眼表现：神经科学领域收入12.49亿元，增长37.3%；抗肿瘤领域收入8.74亿元，增长41.1%；自身免疫领域收入8.78亿元，增长3.3%。研发投入达10.28亿元，占收入的28.7%，彰显公司对创新的持续投入。</p>\n\n<p>分析人士指出，先声药业未来发展潜力巨大。公司创新药管线超过60项，新增科唯可与恩泽舒两款创新药获批，多个研发项目取得重要进展。国际合作方面，公司与艾伯维达成SIM0500三特异性抗体许可选择权协议，展现了自主创新平台的实力。未来催化剂包括创新药管线临床推进、先必新舌下片海外拓展、SIM0500早期数据读出及更多商业开发合作。有分析师给予先声药业16港元的目标价，认为公司业绩增长与估值重塑潜力值得期待。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1132179786","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132179786","pubTimestamp":1756085667,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"8月25日周一盘中，先声药业股价大涨5.04%，引起市场关注。在港股整体市场表现平淡的背景下，先声药业的强劲表现格外引人注目。消息面上，先声药业发布了2025年上半年财报，显示公司业绩表现优异。分析人士指出，先声药业未来发展潜力巨大。国际合作方面，公司与艾伯维达成SIM0500三特异性抗体许可选择权协议，展现了自主创新平台的实力。有分析师给予先声药业16港元的目标价，认为公司业绩增长与估值重塑潜力值得期待。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02096":"先声药业"},"translate_title":"Interpretation of changes | The semi-annual report results are outstanding, Simcere Pharmaceuticals rose 5.04% during the session","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"8月25日周一盘中，先声药业（02096）股价大涨5.04%，引起市场关注。在港股整体市场表现平淡的背景下，先声药业的强劲表现格外引人注目。\n消息面上，先声药业发布了2025年上半年财报，显示公司业绩表现优异。报告期内，公司实现收入35.85亿元人民币，同比增长15.1%；其中创新药业务收入27.76亿元，占比77.4%，同比增长26.0%。归属股东净利润达6.04亿元，增长32.2%。公司三大核心业务领域均有亮眼表现：神经科学领域收入12.49亿元，增长37.3%；抗肿瘤领域收入8.74亿元，增长41.1%；自身免疫领域收入8.78亿元，增长3.3%。研发投入达10.28亿元，占收入的28.7%，彰显公司对创新的持续投入。\n分析人士指出，先声药业未来发展潜力巨大。公司创新药管线超过60项，新增科唯可与恩泽舒两款创新药获批，多个研发项目取得重要进展。国际合作方面，公司与艾伯维达成SIM0500三特异性抗体许可选择权协议，展现了自主创新平台的实力。未来催化剂包括创新药管线临床推进、先必新舌下片海外拓展、SIM0500早期数据读出及更多商业开发合作。有分析师给予先声药业16港元的目标价，认为公司业绩增长与估值重塑潜力值得期待。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}